CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 108 enrolled
Drug / intervention
Losartan 100mg daily +1 moredrug
Likely dose
Losartan 100mg dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02049307
NCT02049307Phase 2Completed
CompareCT.gov

Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial

Hennepin Healthcare Research Institute·interventional·Posted Jan 30, 2014·Updated Dec 10, 2019

In Brief

A Phase 2 clinical trial evaluating Losartan 100mg daily and Matching placebo for Inflammation and Fibrosis. Completed, enrolled 108 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the potential effectiveness of losartan (100mg daily) for reducing inflammation and improving immune recovery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Fibrosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 30, 2014
Enrollment StartOct 16, 2014
Primary CompletionDec 14, 2018
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 12.4 years ago

Interventions

Losartan 100mg dailydrug

Matching placebodrug